The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $224.05

Today's change-6.55 -2.84%
Updated September 1 4:04 PM EDT. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $224.05

Today's change-6.55 -2.84%
Updated September 1 4:04 PM EDT. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc crosses below 125-day moving average

Valeant Pharmaceuticals International Inc closed sharply lower Tuesday, dropping (U.S.)$6.55 or 2.84% to (U.S.)$224.05 and crossing below its 125-day moving average. Over the last five days, shares have gained 1.80% and 56.56% year to date. Shares have outperformed the S&P 500 by 95.47% during the last year.

Key company metrics

  • Open(U.S.) $227.69
  • Previous close(U.S.) $230.60
  • High(U.S.) $229.21
  • Low(U.S.) $222.34
  • Bid / Ask-- / --
  • YTD % change+56.56%
  • Volume2,059,366
  • Average volume (10-day)2,465,152
  • Average volume (1-month)1,989,993
  • Average volume (3-month)1,755,977
  • 52-week range(U.S.) $111.41 to (U.S.) $263.81
  • Beta1.23
  • Trailing P/E92.10×
  • P/E 1 year forward19.84×
  • Forward PEG0.64×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.43
Updated September 1 4:04 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+9.00%

Based on its net profit margin of 9.00%, Valeant Pharmaceuticals International Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX2.72%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue2,7322,1912,2802,056
Total other revenue--------
Total revenue2,7322,1912,2802,056
Gross profit2,0471,6161,6901,495
Total cost of revenue685575590561
Total operating expense2,3911,6681,6721,372
Selling / general / administrative686574525504
Research & development81565959
Depreciation / amortization58536586393
Interest expense (income), net operating--------
Unusual expense (income)1779240687
Other operating expenses, total17767-232
Operating income342523608684
Interest income (expense), net non-operating-413-298-225-258
Gain (loss) on sale of assets--------
Other--------
Income before tax-65155590377
Income after tax-5275534276
Income tax, total-138156100
Net income-5374535275
Total adjustments to net income--------
Net income before extra. items-5374535275
Minority interest-1-11-1
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-5374535275
Inc. avail. to common incl. extra. items-5374535275
Diluted net income-5374535275
Dilution adjustment--00--
Diluted weighted average shares344343342341
Diluted EPS excluding extraordinary itemsvalue per share-0.150.211.560.81
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.190.342.821.01